Oral Vitamin A in Acne Vulgaris Preliminary Report

Authors

  • Albert M. Kligman M.D., PH.D.,

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Otto H. Mills Jr. PH.D.,

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author
  • James J. Leyden M.D.,

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Paul R. Gross M.D.,

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Herbert B. Allen M.D.,

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author
  • Robert I. Rudolph M.D.

    1. Duhring Laboratories, Department of Dermatology, University of Pennsylvania School of Medicine and the Simon Greenberg Foundation, Philadelphia, Pennsylvania
    Search for more papers by this author

Abstract

ABSTRACT: Oral vitamin A (retinol) is generally not considered useful in the treatment of acne vulgaris. We conducted a study which showed that retinol was indeed ineffective at the usual doses of 50,000 to 100,000 IU daily. Retinol was highly efficacious in doses of 300,000 units for women and 400,000 to 500,000 units for men, toxicity was slight and limited mainly to skin (xerosis) and mucous membranes (cheilitis).

The danger of hypervitaminosis A in this dosage range has been exaggerated. Retinol is a valuable drug for treating stubborn, severely inflammatory acne vulgaris. It is administered until the disease is brought under control, usually within three to four months. Then the dosage is progressively reduced relying on conventional drugs to keep the disease in abeyance.

Ancillary